These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 212063)

  • 1. The molecular mechanisms of heparin action III. The anticoagulant properties of polyanetholesulfonate.
    Walker FJ; Esmon CT
    Biochem Biophys Res Commun; 1978 Aug; 83(4):1339-46. PubMed ID: 212063
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of polyanetholesulphonic acid and xylan sulphate on antithrombin III activity.
    Kindness G; Williamson FB; Long WF
    Biochem Biophys Res Commun; 1979 Jun; 88(3):1062-8. PubMed ID: 223567
    [No Abstract]   [Full Text] [Related]  

  • 3. The anticoagulant properties of mast cell product, chondroitin sulphate E.
    Scully MF; Ellis V; Seno N; Kakkar VV
    Biochem Biophys Res Commun; 1986 May; 137(1):15-22. PubMed ID: 3087353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of thrombin-catalyzed reactions in blood coagulation and platelet activation by heparin fractions in the absence of antithrombin III.
    Baruch D; Lindhout T; Wagenvoord R; Hemker HC
    Haemostasis; 1986; 16(2):71-81. PubMed ID: 3086193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of pentosan polysulphate (SP54) and heparin. I: Mechanism of action on blood coagulation.
    Fischer AM; Barrowcliffe TW; Thomas DP
    Thromb Haemost; 1982 Apr; 47(2):104-8. PubMed ID: 6179182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo effects of low molecular weight heparins on experimental thrombosis and bleeding.
    Hirsh J
    Haemostasis; 1986; 16(2):82-6. PubMed ID: 3710297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of a sulfated polysaccharide on antithrombin III.
    Czapek EE; Kwaan HC; Szczecinski M
    J Lab Clin Med; 1980 Jun; 95(6):783-90. PubMed ID: 6155418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetic analysis of various heparin fractions and heparin substitutes in the thrombin inhibition reaction.
    Pletcher CH; Cunningham M; Nelsestuen GL
    Biochim Biophys Acta; 1985 Jan; 838(1):106-13. PubMed ID: 2578296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticoagulant properties of heparin preparations from different animal sources with equivalent high affinity for antithrombin III.
    Nagasawa K; Uchiyama H
    J Biochem; 1984 Mar; 95(3):619-26. PubMed ID: 6725227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for a plasma inhibitor of the heparin accelerated inhibition of factor Xa by antithrombin III.
    MacGregor IR; Lane DA; Kakkar VV
    Biochim Biophys Acta; 1979 Sep; 586(3):584-93. PubMed ID: 476156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular weight of heparin versus biologic activity. Some additional considerations.
    Losito R; Losito C
    Semin Thromb Hemost; 1985 Jan; 11(1):29-33. PubMed ID: 2579437
    [No Abstract]   [Full Text] [Related]  

  • 12. Heparin-catalyzed inhibitor/protease reactions: kinetic evidence for a common mechanism of action of heparin.
    Griffith MJ
    Proc Natl Acad Sci U S A; 1983 Sep; 80(18):5460-4. PubMed ID: 6577437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heparin, antithrombin, and abnormal clotting.
    Rosenberg RD
    Annu Rev Med; 1978; 29():367-78. PubMed ID: 77142
    [No Abstract]   [Full Text] [Related]  

  • 14. The characteristics of anticoagulation by covalently immobilized heparin.
    Miura Y; Aoyagi S; Kusada Y; Miyamoto K
    J Biomed Mater Res; 1980 Sep; 14(5):619-30. PubMed ID: 7349668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the mechanism of heparin action by modification of its structure.
    Danishefsky I
    Fed Proc; 1977 Jan; 36(1):33-5. PubMed ID: 830555
    [No Abstract]   [Full Text] [Related]  

  • 16. Selective disruption of heparin and antithrombin-mediated regulation of human factor IX.
    Westmark PR; Tanratana P; Sheehan JP
    J Thromb Haemost; 2015 Jun; 13(6):1053-63. PubMed ID: 25851619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo correlation of clotting protease activity: effect of heparin.
    Gitel SN; Stephenson RC; Wessler S
    Proc Natl Acad Sci U S A; 1977 Jul; 74(7):3028-32. PubMed ID: 268650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulant activity of a bacterial glycopeptide.
    Akoum A; Josefonvicz J; Sigot M
    Thromb Res; 1990 Oct; 60(1):9-18. PubMed ID: 2126150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased heparin sensitivity of cyclohexanedione-modified factor Xa.
    Blaskó G; Machovich R
    Thromb Haemost; 1979 Aug; 42(2):556-63. PubMed ID: 505364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombin III and heparin.
    Barrowcliffe TW; Johnson EA; Thomas D
    Br Med Bull; 1978 May; 34(2):143-50. PubMed ID: 350337
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.